Skip to content

Study · Animal study (in vivo) · rat · 2025

8 results

Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats.

Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, Boban Blagaic A, Beketic Oreskovic L, Oreskovic I, Ziger T, Novinscak T, Krezic I, Strbe S and 8 more

Show all authors

Drinkovic M, Brkic F, Popic J, Skrtic A, Seiwerth S, Staresinic M, Sikiric P, Brizic I

Pharmaceutics16 Jan 2025Cited by 6 (Europe PMC)

PMID39861766 (opens in a new tab)PMCIDPMC11768438 (opens in a new tab)DOI10.3390/pharmaceutics17010119 (opens in a new tab)PepBankPUB-39861766
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

BackgroundThis is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.MethodsPharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).ResultsImmediately post-injury, and at 1, 2, 3, 5, 7, 14, 21, 28, 60, and 90 days post-injury, quadriceps muscle-to-bone detachment showed definitive healing failure (impaired walking and permanent knee flexure). Contrarily, macro/microscopic, ultrasonic, magnetic resonance, biomechanical, and functional assessments revealed that BPC 157 therapy recovering effects for all time points were consistent. All parameters of the walking pattern fully improved, and soon after detachment and therapy application, muscle approached the bone, leaving a minimal gap (on ultrasonic assessment), and leg contracture was annihilated. The healing process occurs immediately after detachment from both sides: the muscle and the bone. The reattachment fibers from the ends of the muscle could be traced into the new bone formed at the surface (note, at day 3 post-detachment, increased mesenchymal cells occurred with periosteum reactivation). Consequently, at 3 months, the form was stable, and the balance between the muscle and bone was the following: well-organized bone, newly formed as more cortical bone providing a narrower bone marrow space, and the muscle and mature fibers were oriented parallel to the bone axis and were in close contact with bone.ConclusionsTherefore, to achieve quadriceps muscle-to-bone reattachment, the BPC 157 therapy reversing course acts from the beginning, resolving an otherwise insurmountable deleterious course.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment, per-oral BPC‑157 therapy improved all parameters of the walking pattern.

    In plain wordsIn rats with a detached thigh muscle, BPC‑157 by mouth improved all measures of walking.

    Peptide
    BPC-157
    Outcome
    IncreaseWalking pattern
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    All parameters of the walking pattern fully improved
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment, BPC‑157 therapy brought the muscle close to the bone, leaving a minimal gap on ultrasonic assessment.

    In plain wordsIn rats with a detached thigh muscle, BPC‑157 left only a small gap between muscle and bone on ultrasound.

    Peptide
    BPC-157
    Outcome
    DecreaseMuscle-to-bone gap on ultrasound
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    muscle approached the bone, leaving a minimal gap (on ultrasonic assessment)
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment, BPC‑157 therapy abolished leg contracture.

    In plain wordsIn rats with a detached thigh muscle, BPC‑157 removed the stiff, bent leg.

    Peptide
    BPC-157
    Outcome
    DecreaseLeg contracture
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    leg contracture was annihilated.
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment, BPC‑157 therapy produced consistent recovery at all time points across macroscopic, microscopic, ultrasonic, MRI, biomechanical and functional assessments.

    In plain wordsIn rats with a detached thigh muscle, BPC‑157 gave steady signs of recovery at every time point on all tests.

    Peptide
    BPC-157
    Outcome
    IncreaseRecovery across macro/microscopic, ultrasonic, MRI, biomechanical and functional assessments
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    Contrarily, macro/microscopic, ultrasonic, magnetic resonance, biomechanical, and functional assessments revealed that BPC 157 therapy recovering effects for all time points were consistent.
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment, the healing process under BPC‑157 therapy began immediately after detachment from both the muscle and the bone side.

    In plain wordsIn rats with a detached thigh muscle given BPC‑157, healing started right away at both the muscle and the bone.

    Peptide
    BPC-157
    Outcome
    Not applicableTiming of muscle and bone healing
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    The healing process occurs immediately after detachment from both sides: the muscle and the bone.
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment, reattachment fibers from the muscle ends could be traced into newly formed bone at the surface.

    In plain wordsIn rats with a detached thigh muscle given BPC‑157, fibers from the muscle grew into new bone.

    Peptide
    BPC-157
    Outcome
    IncreaseReattachment fibers into new bone
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    The reattachment fibers from the ends of the muscle could be traced into the new bone formed at the surface
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment given BPC‑157, mesenchymal cells increased with periosteum reactivation at day 3 after detachment.

    In plain wordsIn rats with a detached thigh muscle given BPC‑157, bone-forming cells increased on day 3.

    Peptide
    BPC-157
    Outcome
    IncreaseMesenchymal cells and periosteum reactivation at day 3
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    increased mesenchymal cells occurred with periosteum reactivation
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with quadriceps muscle-to-bone detachment given BPC‑157, at 3 months the bone was well organized with more cortical bone and a narrower marrow space, and mature muscle fibers lay parallel to the bone axis in close contact with bone.

    In plain wordsIn rats with a detached thigh muscle given BPC‑157, bone and muscle looked well organized and in close contact after 3 months.

    Peptide
    BPC-157
    Outcome
    Not applicableMuscle and bone structure at 3 months
    Study

    ratn: not reported in source

    Quadriceps muscle-to-bone detachment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 µg/kg/day and 10 ng/kg/day · oralAs given in this study (rat).

    Source sentences

    Summary
    Consequently, at 3 months, the form was stable, and the balance between the muscle and bone was the following: well-organized bone, newly formed as more cortical bone providing a narrower bone marrow space, and the muscle and mature fibers were oriented parallel to the bone axis and were in close contact with bone.
    2 context sentences
    Summary · context
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Summary · context
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.